Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

20260 citationsJournal Articlegreen Open Access

Authors

Marine Boudot de la Motte · Fondation de Rothschild

A. Gavoille · Université Claude Bernard Lyon 1

Caroline Papeix · Fondation de Rothschild

Bertrand Audoin · Assistance Publique Hôpitaux de Marseille

Xavier Ayrignac · Centre Hospitalier Universitaire de Montpellier

Bertrand Bourre · Université de Rouen Normandie

Jonathan Ciron

Abstract

The low risk of disease reactivation found in this study suggests that discontinuing treatment may be considered in selected adult patients with MOGAD. Future clinical trials are necessary to confirm these results and establish guidelines in this situation.

Topics & Keywords

Platelet Disorders and Treatments Immunodeficiency and Autoimmune Disorders Neurogenesis and neuroplasticity mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Neurology

DOI: 10.1001/jamaneurol.2026.0268

Field-Weighted Citation Impact: 0.00